Enorama Pharma AB (ERMA) — Cash Flow-to-Debt Ratio
Enorama Pharma AB (ERMA) has a Cash Flow-to-Debt Ratio of -0.20x as of March 2026, meaning its operating cash flow of Skr-12.09 Million could theoretically repay 0% of its total liabilities (Skr59.58 Million) in one year. See ERMA FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Enorama Pharma AB Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Enorama Pharma AB across 12 annual periods. For the full cash flow conversion analysis, see Enorama Pharma AB cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Enorama Pharma AB (2014–2025)
Year-by-year debt coverage analysis for Enorama Pharma AB. Check ERMA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.87x | Skr-59.26 Million | Skr31.71 Million | ▲ +57.7% |
| 2024 | -4.41x | Skr-35.70 Million | Skr8.09 Million | ▼ -58.4% |
| 2023 | -2.79x | Skr-41.35 Million | Skr14.85 Million | ▼ -45.3% |
| 2022 | -1.92x | Skr-32.96 Million | Skr17.20 Million | ▼ -87.9% |
| 2021 | -1.02x | Skr-30.16 Million | Skr29.58 Million | ▼ -73.5% |
| 2020 | -0.59x | Skr-23.00 Million | Skr39.13 Million | ▲ +21.7% |
| 2019 | -0.75x | Skr-26.56 Million | Skr35.40 Million | ▼ -22.5% |
| 2018 | -0.61x | Skr-13.36 Million | Skr21.81 Million | ▲ +25.3% |
| 2017 | -0.82x | Skr-6.67 Million | Skr8.13 Million | ▲ +39.0% |
| 2016 | -1.34x | Skr-6.11 Million | Skr4.55 Million | ▼ -840.8% |
| 2015 | 0.18x | Skr480.00K | Skr2.64 Million | ▼ -38.9% |
| 2014 | 0.30x | Skr307.00K | Skr1.03 Million | — |